SEC Filing Summary
Entity and period: The filing identifies the registrant as Apollo Medical Holdings, Inc., not Astrana Health, Inc. It is an unaudited Form 10-Q for the three months ended April 30, 2013; the company refers to this as fiscal 2014. The discrepancy with the requested company and “2013 Q1” period should be verified.
Business context
Apollo described itself as a California physician-centric healthcare management company serving Medicare, commercial and Medi-Cal patients. It reported a network of more than 300 physicians and services at over 28 hospitals and long-term acute-care facilities. In February 2013, its subsidiary began managing newly formed Maverick Medical Group (MMG), a risk-contracting IPA; Apollo consolidated MMG from the agreement date. ApolloMed ACO and MMG had no revenue in the quarter.
Financial results and liquidity
| Metric | Three months ended April 30, 2013 | Comparable 2012 period |
|---|---|---|
| Revenue | $2.447 million | $1.632 million |
| Gross profit / margin | $586,073 / 24.0% | $303,185 / 18.6% |
| Operating expenses | $1.298 million | $356,338 |
| Operating loss | $711,972 | $53,153 |
| Net loss | $849,115 | $157,356 |
| Operating cash flow | $12,972 provided | $131,160 used |
- Revenue increased 49.9%; management attributed growth mainly to new hospital contracts, same-market growth and expanded services, as well as the 2012 acquisition of VMM.
- Operating margin was negative 29.1%, versus negative 3.3% in the prior-year quarter. G&A rose to $1.291 million from $351,547, including higher stock-based compensation, professional fees, growth-related staffing and costs for the ACO and MMG initiatives.
- Cash and cash equivalents were $1.576 million at April 30, up from $1.177 million at January 31. Current assets were $3.048 million and current liabilities $2.287 million, implying working capital of about $761,000.
- Reported borrowings comprised $594,745 of current notes payable and $2.036 million of long-term convertible notes, or about $2.631 million total. The company also had a $94,745 balance on a $100,000 credit line due June 5, 2013; its amended $500,000 senior secured note matures October 15, 2013.
- Financing activities provided $389,000, including $300,000 of subscribed stock proceeds held in escrow and $89,000 net proceeds from 9% convertible notes. Investing activities used $3,199.
Changes, outlook and risks
- Despite higher revenue and gross margin, losses widened substantially, principally from increased non-cash stock compensation and spending on new initiatives. Interest expense declined to $127,493 from $224,036, partly because the 2012 comparison included additional debt-discount amortization.
- Management said its operating plan anticipated operating losses throughout fiscal 2014 and warned that liquidity might be insufficient for the next 12 months, raising substantial doubt about the company’s ability to continue as a going concern. It said failure to raise substantial additional capital in time could force cessation of operations.
- The company had raised $980,000 gross from 9% convertible notes through April 30 and received $300,000 for a private placement of up to 7.5 million shares at $0.40 per share; the stock proceeds remained in escrow, with closing anticipated around July 31, 2013. No assurance was given that financing plans would succeed.
- Three customers represented 18%, 18% and 17% of quarterly revenue; three customers represented 26%, 10% and 10% of accounts receivable at period end. MMG and the ACO may require substantial working capital, with no assurance they will generate sufficient cash flow.
- Management reported disclosure controls and internal control over financial reporting were ineffective, citing three material weaknesses: lack of written control documentation, insufficient segregation of duties, and inadequate review and supervision. Remediation was underway.
- The filing discusses ordinary-course malpractice and other legal claims, insurance adequacy and regulatory compliance risks. Management did not expect pending matters to have a material adverse effect, but noted outcomes are uncertain. It reported no off-balance-sheet arrangements.
Most important facts to verify
- Confirm the requested company and period: this filing is for Apollo Medical Holdings, Inc. and the quarter ended April 30, 2013.
- Verify the status and closing of the $300,000 equity placement held in escrow and whether further capital was raised.
- Check repayment or refinancing of the credit line and senior secured note due in June and October 2013, respectively.
- Monitor cash burn, operating losses, and funding needs for MMG and ApolloMed ACO against the disclosed going-concern uncertainty.
- Assess progress in remediating the disclosed material weaknesses and the continuing effect of stock-based compensation and customer concentration.